Switching from natalizumab to fingolimod in multiple sclerosis: A French prospective study

JAMA Neurology

Volumn 71, Issue 4, 2014, Pages 436-441

  Cohen, Mikael ^a   Maillart, Elisabeth ^b   Tourbah, Ayman ^c   De Sèze, Jérôme ^d   Vukusic, Sandra ^e   Brassat, David ^f   Anne, Olivier ^g   Wiertlewski, Sandrine ^h   Camu, William ⁱ   Courtois, Sylvie ^j   Ruet, Aurélie ^k   Debouverie, Marc ^l   Le Page, Emmanuelle ^m   Casez, Olivier ⁿ   Heinzlef, Olivier ^o   Stankoff, Bruno ^p   Bourre, Bertrand ^q   Castelnovo, Giovanni ^r   Rico, Audrey ^s   Berger, Eric ^t   Camdessanche, Jean Philippe ^u   Defer, Gilles ^v   Clavelou, Pierre ^w,aa   Al Khedr, Abdullatif ^x   Zephir, Hélène ^y   Fromont, Agnès ^z   Papeix, Caroline ^b   Brochet, Bruno ^j   Pelletier, Jean ^r   Lebrun, Christine ^a   Barth, Pascal ^aa   Blanc, Frederic ^d   Boulay, Clotilde ^j   Chambaud, Loic ^j   Collongues, Nicolas ^d   Coustans, Marc ^aa   Creange, Alain ^aa   Derouiche, Faycal ^j   Edan, Gilles ^m   Fleury, Marie ^d   Gout, Olivier ^b   Guennoc, Anne Marie ^aa   Kopf, Audrey ^aa   Labauge, Pierre ⁱ   Lallement, Francois ^aa   Laplaud, David ^h   Louiset, Pierre ^k   Malikova, Irina ^s   Moreau, Thibault ^z   Ouallet, Jean Christophe ^k   Pittion, Sophie ^l   Rouhart, Francois ^aa   Rumbach, Lucien ^t   Seeldrayers, Pierrette ^aa   Taithe, Frederic ^aa   Taurin, Gregory ^aa   Thouvenot, Eric ^r   Vermersch, Patrick ^y   Zaenker, Christian ^aa   more..

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g Department of Neurology University Hospital of la Rochelle   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER DE MULHOUSE   (France)

^k BORDEAUX UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF NANCY   (France)

^m RENNES UNIVERSITY HOSPITAL   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o Hospital of Poissy   (France)

^p HÔPITAL TENON   (France)

^q ROUEN UNIVERSITY HOSPITAL   (France)

^r NÎMES UNIVERSITY HOSPITAL   (France)

^s University Hospital of Marseille   (France)

^t UNIVERSITY HOSPITAL OF BESANÇON   (France)

^u UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^v CAEN UNIVERSITY HOSPITAL   (France)

^w UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^x AMIENS UNIVERSITY HOSPITAL   (France)

^y LILLE UNIVERSITY HOSPITAL   (France)

^z DIJON UNIVERSITY HOSPITAL   (France)

^aa NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; NATALIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DRUG SUBSTITUTION; FEMALE; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; PROSPECTIVE STUDIES; RISK FACTORS; SPHINGOSINE; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84899004764     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.6240     Document Type: Article

References (15)

1. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol. 2010;68(3): 395-399.
2. Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68(3): 392-395.
3. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68(2): 186-191.
4. Borriello G, Prosperini L, Marinelli F, Fubelli F, Pozzilli C. Observations during an elective interruption of natalizumab treatment: A post-marketing study. Mult Scler. 2011;17(3): 372-375.
5. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22): 1858-1865.
6. Naismith RT, Bourdette D. Interruption of natalizumab therapy for multiple sclerosis: what are the risks? Neurology. 2011;76(22): 1854-1855.
7. Borriello G, Prosperini L, Mancinelli C, Giannì C, Fubelli F, Pozzilli C. Pulse monthly steroids during an elective interruption of natalizumab: A post-marketing study. Eur J Neurol. 2012;19(5): 783-787.
8. Magraner MJ, Coret F, Navarré A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study. J Neurol. 2011;258(10): 1805-1811.
9. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2): 143-152.
10. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler. 2012;18(11): 1640-1643.
11. Ghezzi A, Baroncini D, Annovazzi PO, Bianchi A, Minonzio G, Comi G. Fromnatalizumab to fingolimod: an observational study of 32 patients. In: Final Programme: 28th Congress of the European Committee for Treatment and Research Into Multiple Sclerosis;October 10-13, 2012; Lyon, France. Lyon, France: European Committee for Treatment and Research Into Multiple Sclerosis; 2012. Poster 938. http://www.posters2view.com/ectrims2012 /view.php?nu=857. Accessed January 19, 2013.
12. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler. 2012;18(11): 1650-1652.
13. Daelman L, Maitrot A, Maarouf A, Chaunu MP, Papeix C, Tourbah A. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012;18(11): 1647-1649.
14. Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Mult Scler. 2013;19(9): 1236-1237.
15. Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol. 2013;260(5): 1382-1387.